European Journal of Clinical Pharmacology

, Volume 30, Issue 5, pp 541–547 | Cite as

Studies on the antihypertensive effect of single doses of the angiotensin converting enzyme inhibitor ramipril (HOE 498) in man

  • R. O. B. Böhm
  • M. A. van Baak
  • K. H. Rahn
Originals

Summary

The time course of the blood pressure lowering effect and the dose-response relationship of the new angiotensin converting enzyme inhibitor ramipril (HOE 498) were studied in 8 patients with essential hypertension. As compared with placebo, a single oral dose of 2.5 mg ramipril lowered systolic and diastolic blood pressure. The antihypertensive action of single oral doses of 5, 7.5 and 10 mg ramipril was more pronounced. No change in heart rate occurred. Angiotensin converting enzyme activity was suppressed after all doses of ramipril studied. Plasma renin activity increased after 2.5 mg and 5 mg ramipril. Plasma aldosterone was not affected by 2.5 mg, but it fell after 5 mg ramipril. Thus, ramipril produced prolonged inhibition (more than 12 hours) of angiotensin converting enzyme activity and lowered blood pressure in patients with essential hypertension.

Key words

ramipril (HOE 498) hypertension angiotensin converting inhibition dose-response relationship time course 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Becker RHA, Schölkens BA, Metzger H, Schulze KJ (1984) Pharmacological properties of the new orally active converting enzyme inhibitor HOE 498. Arzneimittelforsch 34: 1411–1416Google Scholar
  2. Becker RHA, Schölkens BA, Unger Th, Linz W (1983) HOE 498: An orally active nonsulphydryl ACE-inhibitor. Naunyn Schmiedebergs Arch Pharmacol 324: R42Google Scholar
  3. Böhm R, van Baak M, Mooy J, Rahn KH (1985) Studies of the antihypertensive effect of the angiotensin-converting enzyme inhibitor HOE 498 in man. Naunyn Schmiedebergs Arch Pharmal 330 [Suppl]: R47Google Scholar
  4. Brunner HR, Gavras H, Waeber B, Kersha GR, Turini GA, Kukovich RA, McKinstry DN, Gavras J (1979) Oral angiotensin-converting enzyme inhibitor in long-term treatment of hypertensive patients. Ann Int Med 90: 19–23Google Scholar
  5. Brunner DB, Desponds G, Biollaz J, Keller J, Ferber F, Gavras H, Brunner HR, Schelling JL (1981) Effect of a new angiotensin converting enzyme inhibitor MK 421 and its lysine analogue on the components of the renin system in healthy subjects. Br J Clin Pharmacol 11: 461Google Scholar
  6. Bussien JP, Nussberger J, Porchet M, Waeber B, Brunner HR, Perisic M, Tansey MJ, Bomm M, Hajdu P (1985) The effect of the converting enzyme inhibitor HOE 498 on the renin angiotensin system of normal volunteers. Naunyn Schmiedebergs Arch Pharmacol 329: 63–69Google Scholar
  7. Davies RO, Jevin JD, Kramsch DK, Walter JF, Moncloa F (1984) Enalapril worldwide experience. Am J Med 77 [Suppl]: 23–35Google Scholar
  8. Felder K, Witte PU (1984) Effects of the new oral angiotensin converting enzyme inhibitor 2-[N-[(S)-1-Ethoxycarbonyl-3-phenylpropyl]-L-alanyl]-(1S,3S,5S)-2-azabicyclo[3.3.0]octane-3-carboxylic acid (HOE 498) in essential hypertension. Arzneimittelforsch 34: 1452–1454Google Scholar
  9. Ferguson RK, Vlasses PH, Swanson BN, Mojaverian P, Hichens M, Irvin JD, Huber PB (1982) Effects of enalapril, a new converting enzyme inhibitor in hypertension. Clin Pharmacol Ther 32: 48–53Google Scholar
  10. Frohlich ED, Cooper RA, Lewis EJ (1984) Review of the overall experience of captopril in hypertension. Arch Intern Med 144: 1441–1444Google Scholar
  11. Heel RC, Brogden RN, Speight TM, Avery GS (1980) Captopril: A preliminary review of its pharmacological properties and therapeutic efficacy. Drugs 20: 409–452Google Scholar
  12. Henquet JW, Kho T, Schols M, Thijssen H, Rahn KH (1981) The sympathetic nervous system and the renin-angiotensin system in borderline hypertension. Clin Sci 60: 25–31Google Scholar
  13. Jackson B, McGrath BP, Johnson CJ (1982) Correlation between angiotensin converting enzyme inhibition and the acute hypotensive response to MK 421 in essential hypertension. Clin Exp Pharmacol Physiol [Suppl 7]: 99–104Google Scholar
  14. Johnston CI, Jackson B, McGrath B, Matthews G, Arnolda L (1983) Relationship of antihypertensive effect of enalapril to serum MK-422 levels and angiotensin converting enzyme inhibition. J Hypertension 1 [suppl 1]: 71–75Google Scholar
  15. Johnston CI, Arnolda L, Hiwatari M (1984) Angiotensin-converting enzyme inhibitors in the treatment of hypertension. Drugs 27: 271–277Google Scholar
  16. Lijnen P, Amery A, Fagard R, Corvol P (1978) Direct radioimmunoassay of plasma aldosterone in normal subjects. Clin Chim Acta 84: 305–314Google Scholar
  17. Manhem PJO, Ball SG, Morton JJ, Murray GD, Leckie BJ, Fraser R, Robertson JI (1985) A dose-response study of HOE 498, a new non-sulphydryl converting enzyme inhibitor, on blood pressure, pulse rate and the renin-angiotensin-aldosterone system in normal man. Br J Clin Pharmacol 20: 27–35Google Scholar
  18. Riley LJ, Vlasses PH, Ferguson RK (1985) Clinical pharmacology and therapeutic applications of the new oral converting enzyme inhibitor enalapril. Am Heart J 109: 1085–1089Google Scholar
  19. Ryan JW, Chung A, Ammons C, Carlton ML (1977) A simple radio-assay for angiotensin converting enzyme. Biochem J 167: 501–504Google Scholar
  20. Schölkens BA, Becker RHA, Kaiser J (1984) Cardiovascular and antihypertensive activities of the novel non-sulphydryl converting enzyme inhibitor HOE 498. Arzneimittelforsch 34: 1417–1425Google Scholar
  21. Shoback DM, Williams GH, Swartz SL, Davies RO, Hollenberg NK (1983) Time course and effect of sodium intake on vascular and hormonal responses to enalapril (MK 421) in normal subjects. J Cardiovasc Pharmacol 5: 1010–1018Google Scholar
  22. Unger T, Ganten D, Lang RE, Schölkens BA (1984) Is tissue converting enzyme inhibition a determinant of the antihypertensive efficacy of converting enzyme inhibitors? Studies with the two different compounds, HOE 498 and MK 421, in spontaneously hypertensive rats. J Cardiovasc Pharmacol 6: 872–880Google Scholar
  23. Waeber B, Brunner HR, Brunner DB, Curtet AL, Turini GA, Gavras H (1980) Discrepancy between antihypertensive effect and angiotensin converting enzyme inhibition by captopril. Hypertension 2: 236–242Google Scholar
  24. Witte PU, Irmisch R, Hajdu P, Metzger H (1984a) Pharmacokinetics and pharmacodynamics of a novel orally active angiotensin converting enzyme inhibitor (HOE 498) in healthy subjects. Eur J Clin Pharmacol 27: 577–581Google Scholar
  25. Witte PU, Metzger H, Eckert HG, Irmisch R (1984b) Tolerance and pharmacodynamics of the angiotensin-converting enzyme inhibitor 2-[N-[(S)-1-Ethoxycarbonyl-3-phenylpropyl]-L-alanyl]-(1S,3S,5S)-2-azabicyclo[3.3.0]octane-3-carboxylic acid HOE 498 in healthy volunteers. Arzneimittelforsch 34: 1448–1451Google Scholar

Copyright information

© Springer-Verlag 1986

Authors and Affiliations

  • R. O. B. Böhm
    • 1
  • M. A. van Baak
    • 2
  • K. H. Rahn
    • 1
  1. 1.Department of Medicine, Division of Nephrology, Hypertension, Clinical PharmacologyUniversity of LimburgMaastrichtThe Netherlands
  2. 2.Department of PharmacologyUniversity of LimburgMaastrichtThe Netherlands

Personalised recommendations